Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
Pediatr Dermatol
; 39(2): 273-274, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-35178766
ABSTRACT
We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration. Propranolol, a non-selective ß-adrenergic receptor blocker, is the first-line treatment for infantile hemangiomas. All three infants were exposed to opioids in utero and experienced neonatal abstinence syndrome at birth. We hypothesize that chronic opioid exposure in utero may cause protracted upregulation of ß2-adrenergic receptors in the central nervous system, resulting in increased susceptibility to adverse reactions to propranolol.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Síndrome de Abstinência Neonatal
/
Hemangioma Capilar
/
Hemangioma
Tipo de estudo:
Etiology_studies
Limite:
Humans
/
Infant
/
Newborn
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article